Hospital
Crittenden Community Hospital LLC
Crittenden Community Hospital LLC was paid $3.58M by Medicaid between Nov 2019 and Dec 2024, across 99 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoCRITTENDEN COMMUNITY HOSPITAL LLC
MARION, KY 42064
MARION, KY 42064
33aNPI1053885392assigned 01/21/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.58M
24GClaims108,692
24DCodes billed99
24AFirst – last monthNov 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#33 of 36
Median peer was paid$36.08M
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORRIS, DARREL controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,053 | $11K | |
| 2020 | 15,293 | $274K | |
| 2021 | 22,978 | $631K | |
| 2022 | 26,798 | $1.04M | |
| 2023 | 25,405 | $1.04M | |
| 2024incomplete | 17,165 | $574K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 2,379 | 1,661 | $519K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 3,292 | 2,610 | $490K |
| G0378 | Hospital observation service, per hour | 6.9% | 477 | 303 | $245K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.0% | 1,836 | 1,532 | $181K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.6% | 4,299 | 3,552 | $166K |
| 71046 | Radiologic examination, chest; 2 views | 4.2% | 2,056 | 1,508 | $149K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 415 | 317 | $131K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.6% | 3,377 | 2,848 | $129K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 2,214 | 493 | $109K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 149 | 133 | $92K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 1,569 | 1,048 | $91K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 813 | 558 | $80K |
87 more codes
| 80053 | Comprehensive metabolic panel | 2.1% | 8,690 | $76K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 2,426 | $73K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 157 | $70K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 964 | $66K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 3,679 | $57K |
| 86328 | 1.4% | 1,951 | $52K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 2,246 | $49K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 1,494 | $48K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 4,465 | $48K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 704 | $45K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 16,227 | $45K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 7,474 | $38K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 132 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,314 | $31K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,519 | $30K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,898 | $29K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,535 | $29K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,090 | $29K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 366 | $21K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,192 | $20K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 591 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 46 | $16K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 49 | $16K |
| 96376 | <1% | 202 | $16K | |
| 80061 | Lipid panel | <1% | 1,694 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,033 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 675 | $11K |
| 87634 | <1% | 230 | $11K | |
| 80305 | <1% | 1,234 | $10K | |
| 43249 | <1% | 17 | $10K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 603 | $9K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 76 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $8K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 149 | $8K |
| 84439 | <1% | 1,218 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,323 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 202 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,315 | $7K |
| J2704 | Injection, propofol, 10 mg | <1% | 369 | $7K |
| 81001 | <1% | 2,217 | $6K | |
| 84484 | <1% | 538 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 530 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 74 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 723 | $6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 55 | $5K |
| 81003 | <1% | 1,970 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 367 | $5K |
| 81025 | <1% | 606 | $4K | |
| 82607 | <1% | 361 | $4K | |
| 87481 | <1% | 48 | $4K | |
| 83690 | <1% | 599 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 33 | $3K |
| 83735 | <1% | 642 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 500 | $2K |
| 82728 | <1% | 180 | $2K | |
| 83880 | <1% | 65 | $2K | |
| 87486 | <1% | 66 | $2K | |
| 87581 | <1% | 66 | $2K | |
| 83605 | <1% | 186 | $2K | |
| 82553 | <1% | 164 | $1K | |
| 83550 | <1% | 247 | $1K | |
| 86738 | <1% | 81 | $1K | |
| 83540 | <1% | 298 | $1K | |
| 87807 | <1% | 141 | $1K | |
| 87077 | <1% | 248 | $1K | |
| 73030 | <1% | 14 | $1K | |
| 82550 | <1% | 221 | $1K | |
| 82150 | <1% | 219 | $976.59 | |
| 0011A | <1% | 65 | $893.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 45 | $868.26 |
| 71045 | Radiologic examination, chest; single view | <1% | 14 | $858.11 |
| 73630 | <1% | 14 | $836.88 | |
| 85610 | <1% | 191 | $798.71 | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 17 | $762.70 |
| 85652 | <1% | 120 | $667.84 | |
| 87640 | <1% | 23 | $619.01 | |
| 87653 | <1% | 24 | $548.08 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 66 | $546.62 |
| 87541 | <1% | 17 | $464.90 | |
| 87186 | <1% | 86 | $420.64 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 25 | $347.22 |
| 93246 | <1% | 12 | $329.03 | |
| 0012A | <1% | 19 | $240.00 | |
| 80306 | <1% | 12 | $115.39 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $106.75 |
| 85730 | <1% | 18 | $68.81 | |
| 86308 | <1% | 13 | $42.70 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORRIS, DARREL (COO)
| Provider | Location | Paid |
|---|---|---|
| Lauderdale Community Hospital LLC | Ripley, TN | $1.48M |
| Drumright Community Hospital LLC | Drumright, OK | $1.40M |
| Drumright Community Hospital LLC | Drumright, OK | $916K |
| Crittenden Community Hospital LLC | Marion, KY | $664K |
| Drumright Community Hospital LLC | Drumright, OK | $374K |
| Lauderdale Community Hospital LLC | Ripley, TN | $305K |
| Hillsboro Hospital LLC | Hillsboro, KS | $241K |
| Crittenden Community Hospital LLC | Marion, KY | $113K |
| Crittenden Community Hospital LLC | Fredonia, KY | $30K |
| Sumner Community Hospital LLC | Wellington, KS | $5K |
| Hillsboro Hospital LLC | Hillsboro, KS | $1K |
| Lauderdale Community Hospital LLC | Ripley, TN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.